Five Key Insights From Oncology First Launches

Posted by Ben Hohn on May 31, 2019 9:27:29 AM

Judith Kulich, Jon Roffman, Cody Powers and Renuka Agarwal co-wrote this blog post with Ben Hohn.

Oncology continues to be the leading therapeutic area for first launches by emerging biopharma companies in the United States. Recent ZS analysis identified 125 U.S. biopharma companies with first launches from 2011 to 2018, and 51 of those were for novel drugs. Of these 51,14 were in oncology—the largest number of any therapeutic area.


>
Read More

In Conversation With ZS Experts: How to Compete When You’re Not the First or Best on the Market

Posted by Matilda Males on Mar 15, 2019 10:21:58 AM

Jennifer Curtis co-wrote this blog post with Matilda Males.

While customer experience is not a new concept in pharma, it has been relatively absent as a core strategy for many of the leading oncology companies. Why? Until recently, it hasn’t been necessary. Twenty years ago, the oncology market was dominated by a few key players whose success was driven by single blockbuster drugs that generated years of high returns. Today, the market has exploded. The combination of high unmet need and promising revenue potential has resulted in companies of all sizes dipping their toes into the oncology market. Fourteen of the largest pharma companies have one-third of their late-stage R&D focused exclusively on oncology, and almost 700 companies have one or more assets in late-stage development, according to IQVIA’s 2018 Global Oncology Trends report. We’re also seeing a decline in the duration of clinical trials and faster drug approvals, leading to shorter development life cycles. At the same time, there are fewer clinically differentiated assets that are competing within the same space and with high prices.


>
Read More

Getting a Read on the EU’s Biosimilar Uptake Across Therapeutic Areas

Posted by Christina Corridon on May 31, 2018 8:00:00 AM

Laura Nielsen co-authored this blog post with Christina Corridon. 

Since the first EU biosimilar approval for Sandoz’s Omnitrope 12 years ago, the European biosimilar market has been difficult to predict. The dynamic policy and regulatory environment, differing levels of payer control, and variability in go-to-market approaches and manufacturing necessitate a bit of guesswork when it comes to predicting how a given biosimilar will perform. 


>
Read More

Five Observations From Successful Oncology ‘First Launches’

Posted by Ben Hohn on Aug 14, 2017 10:29:32 AM

Nicholas Martinez and Cody Powers co-wrote this blog post with Ben Hohn.

The stakes are high when preparing to launch a new drug, but for a biopharmaceutical company staring down its first-ever oncology launch, the stakes are even higher. Drug launches in the oncology space have grown increasingly competitive and occur more frequently than in any other therapeutic category. And of the 202 novel drugs approved by the FDA from 2011 to 2016, five were oncology drugs launched in the U.S. by publicly traded newcomers—so-called “first launches.”  


>
Read More